神経芽細胞腫の新しい血中マーカー物質 : Nervous system specific enolase (NSE)

抄録

Serum levels of nervous system-specific enolase (NSE) in patients with neuroblastoma and in control subjects were determined with a sensitive solid-phase sandwich enzyme immunoassay system, using a mono-specific antibody to the γ subnit of rat NSE for solid-phase preparation and for enzyme-labeled antibody. Using this assay system, the NSE in human sera can be estimated with a minimum measurable consentration of 0.6ng γγ equivalent/ml, with less than 10% of coefficients of variation for within-run (n=20) and between-run (n=15) assays. Serum levels of NSE in healthy adults ranged from 1.4-5.7ng/ml (2.87±1.18ng/ml, n=20), and those in control children (1-7 years old) were from 2.6 to 10.8ng/ml (5.76±2.42ng/ml, n=20). Serum samples (n=11) from patients with neuroblastoma contained high levels of NSE, distributing 13.6 to 330ng/ml (mean, 107ng/ml), however those from ganglioneuroblastoma patients were within a normal range (3.0-25.0ng/ml, mean, 8.3ng/ml). These results suggest that the NSE in serum might be a valuable marker substance for the screening and therapeutic monitoring of neuroblastoma.